Experts say the emerging tech can dramatically accelerate advances in drug discovery, diagnostics and precision medicine.

The Triangle’s life sciences sector is in the midst of one of the most significant growth waves in its history. But as the ...

Every life sciences company knows that patient safety is non negotiable, but the way safety is managed—and the value ...

AICA currently supports auditing against 21 CFR Parts 11, 211, and 600, each mapped at the section and subsection levels.

Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved aggressively to shore up pipelines and offset looming revenue losses, according to ...

Caris projects 2026 total revenue in the range of $1.0 billion to $1.02 billion, anticipating molecular profiling growth of approximately 21% to 22%, and therapy selection volume growth of around 20% ...

Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy ...

Exact Sciences Corp. (NASDAQ:EXAS) is one of 15 stocks with the biggest hedge fund momentum, after gaining 31 hedge fund ...

Following a difficult start in 2025, the ever-evolving life sciences segment recovered strongly in the latter half of the year.

The Penn Museum and the Academy of Natural Sciences of Drexel University have discontinued their long-running summer camp ...